Department of Infectious Diseases, Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
The Swedish Reference Group for Antiviral Therapy (RAV), Stockholm, Sweden.
Infect Dis (Lond). 2023 Oct;55(10):725-737. doi: 10.1080/23744235.2023.2234476. Epub 2023 Jul 17.
Influenza causes seasonal epidemics of respiratory infection in all parts of the world. Manifestations of influenza range from mild upper to severe lower respiratory tract infection. Medical risk groups are defined by factors predisposing for development of severe disease and are recommended annual vaccination as a protective measure. The previous Swedish treatment guidelines for influenza were issued in 2011, and a review of current evidence was deemed relevant. An important reason to revisit the guidelines is the recent approval of a novel drug for influenza treatment, baloxavir. Updated Swedish evidence-based guidelines created by a group of experts from various research areas, for the management of influenza are presented here. The work has been made in collaboration with the Public Health Agency of Sweden and the Swedish Reference Group for AntiViral therapy (RAV). The updated guidelines include guidelines for diagnostics, treatment and prophylaxis in special groups, including management of pregnant women and children with influenza. A new section about infection control has been added. Pharmacological treatment is covered in detail with regards to indication and dosage. Additionally, drug resistance and environmental aspects are discussed.
流感在世界范围内引起呼吸道感染的季节性流行。流感的表现从轻度上呼吸道感染到严重下呼吸道感染不等。医学风险群体是由导致严重疾病发展的因素定义的，建议每年接种疫苗作为保护措施。瑞典之前的流感治疗指南于 2011 年发布，对现有证据进行审查被认为是相关的。重新审查这些指南的一个重要原因是最近批准了一种新型流感治疗药物巴洛沙韦。由来自不同研究领域的专家组成的一个小组为流感的管理制定了更新的基于瑞典证据的指南。这项工作是与瑞典公共卫生局和瑞典抗病毒治疗参考小组（RAV）合作进行的。更新的指南包括特殊人群的诊断、治疗和预防指南，包括孕妇和儿童流感的管理。新增了关于感染控制的章节。对药物治疗进行了详细的讨论，包括适应证和剂量。此外，还讨论了耐药性和环境方面的问题。
